In The NewsThe SFJ Pharmaceuticals Group announces agreement with Pfizer to co-develop Dacomitnib as first-line treatment for patients with advances non-small cell cancer.
View the Press Release
MissionThe SFJ Pharmaceuticals Group mission is to accelerate the availability of new and innovative drugs into the world's major markets, by providing not only additional funding, but also strategic development expertise to enable our Pharma and Biotech partners to be as hands off or as hands on as they wish.
Target MarketSFJ Pharmaceuticals Group is primarily focused on funding and / or executing global or regional Phase III studies.
SFJ Pharmaceuticals Group is positioned to develop prescription drugs in any and all therapeutic areas, where there is a clear medical and market need.